# Evaluate the Safety and Efficacy of Canakinumab in Pediatric Patients With Colchicine Intolerant or Colchicine Resistant Familial Mediterranean Fever (FMF)

> **NCT01148797** · PHASE2 · COMPLETED · sponsor: **Novartis Pharmaceuticals** · enrollment: 15 (estimated)

## Conditions studied

- Colchicine Resistant/Intolerant Familial Mediterranean Fever

## Interventions

- **DRUG:** Canakinumab

## Key facts

- **NCT ID:** NCT01148797
- **Lead sponsor:** Novartis Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2010-12
- **Primary completion:** 2012-02
- **Final completion:** —
- **Target enrollment:** 15 (ESTIMATED)
- **Last updated:** 2016-11-18


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01148797

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01148797, "Evaluate the Safety and Efficacy of Canakinumab in Pediatric Patients With Colchicine Intolerant or Colchicine Resistant Familial Mediterranean Fever (FMF)". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT01148797. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*